Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2021-06-08 Earnings Release
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science fournit le résumé de la conférence virtuelle qui s’est tenue le 3 juin 2021 suite à l’interruption volontaire des études cliniques du masitinib
Earnings Release Classification · 1% confidence The document is titled "RESUME DE LA CONFERENCE VIRTUELLE DU 3 JUIN 2021 SUITE A L'INTERRUPTION VOLONTAIRE DES ETUDES CLINIQUES DU MASITINIB" (Summary of the Virtual Conference of June 3, 2021 following the voluntary interruption of Masitinib clinical studies). It explicitly provides a summary of a conference call, including Q&A, featuring medical and management personnel discussing a clinical hold and subsequent stock trading resumption. This content perfectly matches the definition of a Call Transcript (CT), which covers full text transcripts of company conference calls, especially earnings calls which often include Q&A sessions about operational/clinical updates. Although it is a 'resume' (summary), the structure and content strongly suggest it is derived directly from or intended to serve as the official record of the call, making CT the most appropriate classification over a general ER or RPA. FY 2021
2021-06-08 French
AB Science tiendra une conférence virtuelle le jeudi 3 juin 2021 suite à l'annonce de l'interruption volontaire des études cliniques du masitinib
Regulatory Filings Classification · 1% confidence The document is an announcement from AB Science regarding a virtual conference scheduled for June 3, 2021, to discuss the voluntary interruption of clinical studies for Masitinib. The text explicitly details the date, time, participants, and dial-in information for this conference. This type of announcement, which schedules a call to discuss specific corporate or clinical events (especially following a major announcement like study interruption), aligns best with the definition of a Call Transcript (CT) if it were the transcript itself, or an announcement leading up to one. However, since the document is the *announcement* of the conference and includes background information, it functions as a specific type of investor communication. Given the options, it is an announcement about an upcoming event where management will speak. While it is not a formal Earnings Release (ER), it is a specific communication event. The closest fit among the provided codes for an announcement detailing a scheduled call where management will present/discuss matters is often grouped with Call Transcripts (CT) if the content is focused on the call details, or sometimes an Investor Presentation (IP) if it were the slides. Since this is an announcement *about* a conference call, and the content is focused on providing details for that call, it strongly suggests an event that will result in a Call Transcript (CT). However, if we strictly classify the announcement itself, it is a general corporate update. Given the focus on a scheduled call with Q&A involving senior management to discuss a critical clinical development, it is most closely related to the context of a Call Transcript (CT) or a general Investor Presentation (IP). Since it is an announcement *of* a call, and not the call transcript itself, and it is not a standard ER, the most appropriate classification for a scheduled event where management discusses material information is often related to the resulting transcript or presentation. Given the options, and recognizing this is an announcement of a specific event where management will speak, it is best classified as an announcement related to a conference call, which often precedes or is closely related to the 'Call Transcript' category, or potentially a general 'Regulatory Filing' (RNS) if no better fit exists. Since the core purpose is to announce the conference details, and it is not a formal financial report, 'CT' is the most contextually relevant category for the *event* being announced, but 'RNS' is the safest for an announcement of a non-standard event. Let's re-evaluate: It is an announcement of a conference call. This is not a DEF 14A, 10-K, or ER. It is not a dividend (DIV) or capital change (CAP). It is an announcement of a specific event where management will discuss material information. This often falls under RNS or sometimes IP if it were the presentation slides. Given the structure, it is an announcement of a call, which is a form of regulatory/investor communication. I will classify it as RNS as the fallback for specific event announcements that don't fit the core financial reports, although it is highly related to the context of a CT.
2021-06-02 French
AB Science will host a live webcast on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
Call Transcript Classification · 1% confidence The document is an announcement titled "AB SCIENCE WILL HOST A LIVE WEBCAST ON THURSDAY JUNE 3, 2021 FOLLOWING THE VOLUNTARY HOLD IN THE CLINICAL STUDIES OF MASITINIB". It details the date, time, participants, and dial-in information for a conference call where management will discuss a specific corporate/clinical event (suspension of masitinib studies). This format, which includes a scheduled call with Q&A and management participation, is characteristic of a conference call transcript or an announcement leading up to one. Since the text provided is the announcement *about* the call, and it explicitly mentions that the presentation will be followed by a Q&A session, it strongly aligns with the context of an Earnings Call or similar corporate update call. Given the options, 'Call Transcript' (CT) is the most appropriate classification for the material surrounding a scheduled Q&A session, even if this specific text is the invitation rather than the full transcript itself. However, if we strictly follow the 'MENU VS MEAL' rule, this is an announcement *about* an event, not the event's content (like a transcript). Since there is no specific category for 'Webcast Announcement', and it is not a standard financial report (10-K, IR, ER), it could fall under 'Regulatory Filings' (RNS) as a general announcement. But the content is highly specific to a management discussion/Q&A event. Comparing CT (Call Transcript) vs RPA (Report Publication Announcement): This is an announcement about a *call*, not the publication of a formal *report*. Therefore, CT is the best fit as it relates directly to the nature of the event being hosted (a call with Q&A).
2021-06-02 English
AB Science annonce l'interruption volontaire des études cliniques du masitinib au niveau mondial
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a major operational decision: the voluntary interruption of clinical trials for Masitinib following discussions with regulatory authorities (ANSM). This is a significant corporate event announcement concerning drug development and regulatory compliance. It is not a full financial report (10-K, IR), an earnings release (ER), or a formal shareholder vote result (DVA). Since it details a critical operational/regulatory event that impacts the company's pipeline and involves direct communication with regulators regarding safety concerns, it best fits the category of a general regulatory announcement or a significant corporate update that doesn't fit a more specific financial or governance code. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-financial, non-management change announcements that are regulatory in nature, or 'LTR' if it were focused purely on legal proceedings, but this is a proactive safety/development halt. However, since it is a press release announcing a major operational decision based on regulatory feedback, and it doesn't fit the specific financial, management, or capital structure codes, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it strongly resembles a material event disclosure.
2021-06-01 French
AB Science announces a voluntary hold in the clinical studies of masitinib worldwide
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces a major operational decision: the voluntary hold in clinical studies for masitinib due to a potential safety risk (ischemic heart disease). It details consultations with regulatory authorities (ANSM) and the impact on specific ongoing trials. This type of announcement, concerning significant operational or safety developments that impact ongoing drug development and require regulatory interaction, is best classified as a general Regulatory Filing or announcement that doesn't fit the specific financial report categories (10-K, ER, IR) or specific corporate actions (DIV, CAP, MANG). Since it is a press release detailing a significant regulatory/safety event, and it is not a full financial report, a management discussion, or a specific shareholder vote result, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard announcements.
2021-06-01 English
AB Science communicates results from Phase 3 study evaluating masitinib in prostate cancer
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and communicates the results from a Phase 3 study evaluating masitinib in prostate cancer, which was presented during a webcast. It details clinical trial results (AB12003 study), mechanism of action, and includes quotes from Key Opinion Leaders (KOLs) and company background. This structure—announcing key results outside of a formal periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical news. Since it focuses on communicating financial/clinical results immediately upon release, 'ER' (Earnings Release) is the most appropriate fit among the options, even though it's a clinical update rather than strictly quarterly earnings. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP), but the announcement of the findings discussed in those forums. Given the focus on communicating study results, ER is the best fit for a timely results announcement. FY 2021
2021-05-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.